Cencora's Ameer Ali on the operational lift behind the 12-digit NDC shift, the readiness gap across manufacturers and what's at stake for product flow if systems aren't ready in time.
Publication|Articles|September 29, 2023
- Pharmaceutical Commerce - October 2023
- Volume 18
- Issue 5
Pharmaceutical Commerce - October 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Commerce October 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 3 years ago
Taking Pharma's Temperaturealmost 3 years ago
All About the Journeyalmost 3 years ago
Drilling Down On Distributionalmost 3 years ago
Affordability: Who's Responsible?almost 3 years ago
Time to Ax Copay Accumulators?almost 3 years ago
Return of Cash Pay for Drugsalmost 3 years ago
The State of the Pharma Cold Chainalmost 3 years ago
Reshaped Priorities Pave Cold Chain Pathalmost 3 years ago
Counterfeit Meds: Fighting the Forgersalmost 3 years ago
Fortifying Vaccine Supply ChainsAdvertisement
Related to this article
Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.
Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
Informa's invitation-only Leadership Summit returns to CPHI Milan Oct. 6 as executives weigh sourcing, medicine security and reshoring pressure.
The EU's pharma reform makes market protection more conditional. Here is how US drugmakers, especially startups, can adapt and use IP to complement it.
The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
Advertisement
Advertisement